Argenx

70 articles with Argenx

• Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

  5/22/2019

  Halozyme Therapeutics, Inc. announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.

• argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology

  2/4/2019

  argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn

• 

  Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million

  2/4/2019

  Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in San Diego, CA, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.
• 

  The 20 Hottest Pipeline Drugs to Watch in 2019

  1/3/2019

  EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.

• Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab

  12/3/2018

  Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain

• Regulated information – Inside information argenx enters exclusive global collaboration and license agreement with 
Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

  12/3/2018

  argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110)

• argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

  12/3/2018

  argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced  that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)

• 

  Argenx and a Johnson & Johnson Affiliate Ink Deal That Could Hit $1.8 Billion

  12/3/2018

  Argenx, based in Ghent, Belgium, announced a global collaboration and license deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.
• 

  Roche Focuses on T Regulatory Cells in $758 Million Acquisition of Tusk Therapeutics

  9/28/2018

  Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
• 

  AbbVie Exercises Option to Develop Argenx Immuno-Oncology Compound

  8/22/2018

  Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).

• Argenx Announces Closing of U.S. Public Offering for Gross Proceeds of Approximately $26M

  12/19/2017

  Argenx announced today the closing of its public offering in the United States of 5,106,000 ADSs, at a price of $52.00 per ADS, for gross proceeds of approximately $266M.

• 

  argenx Bags $231M in Upsized U.S. IPO

  12/14/2017

  argenx increased the Offering from the initially filed offering size of $150 million.

• argenx Announces Size of Proposed Public Offering in the United States Updated to 3.5 Million ADSs

  12/13/2017

  All of the ADSs in the proposed Offering are to be sold by argenx.

• argenx Announces Launch of Proposed Public Offering in the United States

  12/12/2017

  Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of €0.10 per share. All of the ADSs in the proposed Offering are to be sold by argenx.

• argenx to Provide Updates on Phase I/II Clinical Trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma During American Society of Hematology Annual Meeting

  12/11/2017

  The workshop will be held Monday, December 11th at 12:00 pm EST.

• argenx Reports Positive Topline Results From Phase II Proof-of-Concept Trial of ARGX-113 (Efgartigimod) in Generalized Myasthenia Gravis

  12/11/2017

  Favorable tolerability profile consistent with Phase 1 data.

• argenx Announces Results of Extraordinary Shareholders' Meeting 2017

  11/7/2017

  All proposed resolutions on the agenda for this extraordinary shareholders' meeting were approved.

• Argenx to Host KOL Breakfast Symposium on Pemphigus Vulgaris on November 10, 2017

  11/2/2017

  The event will feature guest speaker Dr. John Stanley, M.D., University of Pennsylvania School of Medicine, who will highlight the treatment landscape and unmet need in PV.

• argenx Launches Phase I trial With Subcutaneous Formulation of ARGX-113

  10/30/2017

  The first subject has been dosed in the Phase I clinical trial.

• Argenx Reports Third Quarter 2017 Financial Results and Provides Business Update

  10/26/2017

  The company announced financial results and provided a business update for the third quarter ended September 30, 2017.